Parenteral iron therapy exacerbates experimental sepsis.
about
Deferoxamine attenuates lipid peroxidation, blocks interleukin-6 production, ameliorates sepsis inflammatory response syndrome, and confers renoprotection after acute hepatic ischemia in pigs.Transferrin saturation ratio and risk of total and cardiovascular mortality in the general population.Parenteral iron formulations differentially affect MCP-1, HO-1, and NGAL gene expression and renal responses to injury.Heme iron polypeptide for the treatment of iron deficiency anemia in non-dialysis chronic kidney disease patients: a randomized controlled trial.A randomized trial of intravenous and oral iron in chronic kidney diseaseDrug insight: Safety of intravenous iron supplementation with sodium ferric gluconate complex.Risk of infection with intravenous iron therapy.Infection risk with bolus versus maintenance iron supplementation in hemodialysis patientsUremia induces proximal tubular cytoresistance and heme oxygenase-1 expression in the absence of acute kidney injuryParenteral iron use: possible contribution to exceeding target hemoglobin in hemodialysis patientsRenal ischemia-reperfusion injury upregulates histone-modifying enzyme systems and alters histone expression at proinflammatory/profibrotic genes.Growth and development alter susceptibility to acute renal injury.Optimizing anemia management in hospitalized patients with end-stage renal disease.Anemia in heart failure: pathophysiologic insights and treatment options.The effect of iron loading and iron chelation on the innate immune response and subclinical organ injury during human endotoxemia: a randomized trial.Iron Loading Exaggerates the Inflammatory Response to the Toll-like Receptor 4 Ligand Lipopolysaccharide by Altering Mitochondrial Homeostasis.Iron deficiency anemia in chronic kidney disease: Uncertainties and cautions.Iron (III) isomaltoside 1000.Physico-chemical properties of the new generation IV iron preparations ferumoxytol, iron isomaltoside 1000 and ferric carboxymaltose.Intravenous iron exposure and outcomes in patients on hemodialysis.Evaluating the effectiveness of IV iron dosing for anemia management in common clinical practice: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS).Parenteral iron compounds sensitize mice to injury-initiated TNF-alpha mRNA production and TNF-alpha release.What are the Considerations in Balancing Benefits and Risks in Iron Treatment?: Emerging Evidence on the Safety of Intravenous Iron in Chronic Kidney Disease.Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: a randomized trial.Hepcidin protects against lethal E. coli sepsis in mice inoculated with isolates from septic patients.Serum Ferritin: Deceptively Simple or Simply Deceptive? Lessons Learned From Iron Therapy in Patients With Chronic Kidney Disease
P2860
Q33398849-D2064472-F285-4F1C-96FA-EEB89342D62AQ33941773-BE45DD3F-D247-4AA2-A0EF-B3A650402C9BQ34085240-6C5E9B0B-6F5F-41DE-A01D-E48D5EED724DQ34628344-3AACA3D1-138C-4B73-93F8-80D1D810CC43Q36108862-B63BA76E-997C-4C74-8BA3-0F1644BEFC0FQ36577123-42ADFB7C-B612-4099-A950-1CBC222AE6FAQ36897822-39D0FECA-9643-48B4-9700-BD99DF32B57DQ36977382-6CD1429A-9E8D-46ED-A9B1-4426599A5F02Q37100070-451702E9-0E7A-4C31-B469-750665B5C92DQ37123216-84B68DC2-E299-4055-A275-DAE1E2837086Q37190248-F1D94125-98DD-4B3B-AB3B-BAFAE773E6EFQ37347589-7BCF2CD8-9DAE-40CD-A116-22CDACD334CAQ37367706-3ABCD9D5-9A88-47FB-81C7-26BD69F178FBQ37445907-C3D65543-B628-406F-9E70-6E740E9D44D4Q38441130-8746DF8E-02C3-4290-BC51-FB63AA8E2596Q38826753-92FF19E2-B35D-402A-B772-379E05E30E82Q38839971-76BE8AF1-F065-404F-A038-F13838722C75Q39399976-0288A350-C73E-4509-A45F-4B0C443C2957Q41173473-C0A1FCF1-9762-4ED4-BAAB-F666F1216CE1Q42975965-D776DF50-C92E-4003-9CBE-7F43B33BBA35Q44676908-F58C0752-9C5C-4B5D-AB04-AD386E56A2ABQ45115192-0ECFC320-8C6C-4A78-B753-03CD74F023BFQ48040293-A530A88A-B17A-4464-BFE5-28047F12C9CFQ51035442-9843727B-8274-45C5-99F2-514AA5F20683Q54203232-B9A03BF4-40F4-43C5-B487-6F185DFCCC22Q57772029-FB3503E3-DD8D-4B2C-A59C-C69C6F27ADFD
P2860
Parenteral iron therapy exacerbates experimental sepsis.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Parenteral iron therapy exacerbates experimental sepsis.
@en
Parenteral iron therapy exacerbates experimental sepsis.
@nl
type
label
Parenteral iron therapy exacerbates experimental sepsis.
@en
Parenteral iron therapy exacerbates experimental sepsis.
@nl
prefLabel
Parenteral iron therapy exacerbates experimental sepsis.
@en
Parenteral iron therapy exacerbates experimental sepsis.
@nl
P2093
P1433
P1476
Parenteral iron therapy exacerbates experimental sepsis.
@en
P2093
Ali C M Johnson
Richard A Zager
Sherry Y Hanson
P304
P356
10.1111/J.1523-1755.2004.00742.X
P407
P577
2004-06-01T00:00:00Z
P5875
P6179
1040011650